Summary. Platelet sensitivity to adenosine diphosphate and prostacyclin in diabetes has been assessed using collision thetry and the concept of 'sticking probability' (the probability of particle union). Twenty Type 1 (insulin-dependent) diabetic men (10 with no or minimal retinopathy and a matched group of 10 with proliferative retinopathy) and 10 age-matched nondiabetic men were studied. Platelets from the 20 diabetic patients required, on average, 37% less adenosine diphosphate to achieve a sticking probability of 0.5 (EDs0) compared with platelets from the non-diabetic subjects (medians 1.50 and 0.95 ]xmol/1, respectively; p <0.01). The platelet prostacyclin response was assessed by the dissociation constant (Ki) for inhibition of adenosine diphosphate-induced aggregation. Platelets from the diabetic patients had similar prostacyclin sensitivity to those from the non-diabetic subjects (medians 0.42 and 0.42 respectively). Diabetic patients with and without retinopathy had similar platelet sensitivity to both adenosine diphosphate and prostacyclin.
The results of most of the studies concerned with platelet aggregation in diabetes mellitus suggest that platelets from diabetic subjects are hypersensitive to pro-aggregating agents in vitro [1, 2] . Prostacyclin is thought to counter the pro-aggregatory behaviour of platelets in vivo [3] , and, although decreased vascular prostacyclin production might not, as first postulated [4] , occur in diabetes [5] , platelet prostacyclin sensitivity may be depressed [6, 71. In the present study, the sensitivity of platelets from normal subjects and from matched diabetic patients both with and without retinopathy to a range of doses of adenosine diphosphate (ADP) and prostacyclin was investigated using a model of platelet aggregation based on particle collision theory [8] . This model allows interpretation of platelet sensitivity to ADP and prostacyclin in terms of 'sticking probability', a measure which reflects the haemostatic function of platelets.
Subjects and methods

Subjects
Twenty Type I diabetic men and 10 male non-diabetic subjects were studied (Table 1) . Informed consent was obtained from each subject before his participation in the study. The diabetic patients were divided into two subgroups according to severity of retinopathy: t 0 had no or minimal retinopathy, as assessed by ophthalmoscopy and fluorescein angiography, and ten had established proliferative retinopathy. No subject had taken medication known to affect platelet function tests during the fortnight before venepuncture.
Methods
The subjects attended fasting and in random order. Blood was taken for use in aggregation studies [8] , for estimation of plasma glucose (glucose oxidase, Boehringer GOD-Perid kit, Lewes, UK), and for determination of glycosylated haemoglobin [9] . Aggregation studies for each subject were performed as described by Davis and Bown [8] using platelet-rich plasma with a standard count of 250,000/ml. A conventional aggregometer (Payton Associates, Buffalo, Illinois, USA) provided the data required for collision theory analysis: a platelet dilution curve (the forms of which were 275 similar for both diabetic and non-diabetic subjects) and aggregation tracings for ten final ADP concentrations ranging from 0.2 to 4.0 am 9
These doses provoked a range of aggregation for minimal to irreversible in all subjects.
The collision theory model was used to calculate a 'sticking probability' (the probability of particle union following collision) for each ADP dose at the point of maximal first-phase aggregation [8] . The model is based on a constant relationship between the collision rate and number of particles present in the aggregometer curette. A proportion of such collisions results in particle union following addition of submaximal doses of ADP, with a theoretical 'sticking probability' of unity at an 'infinite' dose. A dose-response curve can be easily constructed.
In addition to a dose-response curve for ADP alone, aggregation tracings for each of four doses of ADP (0.4, 0.8, 1.2, and 3.0 .urn 9 in the presence of each of four doses of prostacyclin (0.2, 0.4, 0.6 and 1.0 ng/ml) were obtained. The prostacyclin was added to standard platelet-rich plasma from a concentrated solution (0.1 mg/pJ in 0.05 mol/1 Tris/HCl, ph 9.0, at 4 ~ with the ADP dose added 30 s later.
The EDs0 (the dose required for a half-maximal response) of the ADP 'sticking probability' dose-response curve was taken as a measure of platelet sensitivity to ADP for each subject. From the EDs0's of the ADP dose-response curves in the presence of each prostacyclin concentration, an inhibition constant (Ki) for prostacyclin was calculated [10] . This enabled a measure of platelet prostacyclin sensitivity to be obtained for each subject which was independent of platelet sensitivity to ADP alone.
Statistical analysis
All data are expressed as medians and absolute ranges. Non-parametric tests (Mann-Whitney U test) with two-tailed levels of significance were used to analyse the data.
Results
The non-diabetic subjects had significantly higher EDs0 values for the ADP dose-response curves (where, by definition, the 'sticking probability' is 0.5) than those of the 20 diabetic patients (Mann-Whitney U test, p < 0.01 ; Fig. 1 ). However, the EDs0 values of the diabetic patients with no or minimal retinopathy were similar to those with proliferative retinopathy.
The effect of adding prostacyclin to platelets before ADP is seen in Figure 2 . The EDs0 values increased, indicating that more ADP is required to produce a 'sticking probability' of 0.5 in the presence of increasing final prostacyclin concentrations. However, the Ki values for prostacyclin-induced inhibition of ADP-provoked aggregation were similar for the control subjects (median, 0.42, range 0.32-0.69) and diabetic patients (0.42, 0.17-0.65; p > 0.1). There was also no significant difference between the Ki values of the diabetic patients with no or minimal retinopathy (0.48, range 0.17-0.65) and those with proliferative retinopathy (0.39, range 0.27-0.57).
There was no significant correlation between age, duration of diabetes, daily insulin dose, fasting plasma glucose concentration or glycosylated haemoglobin levels, and either EDs0 or Ki for the control subjects or the 20 diabetic patients.
Discussion
Although the control and diabetic groups were wellmatched in the present study, platelets from the diabetic subjects were found to be hypersensitive to ADP in vitro. This result is consistent with the findings of other authors using alternative methods [1, 2] . The increased 'sticking probability' of platelets from diabetic patients lends weight to the suggestion that increased numbers of platelet aggregates circulate in diabetes [11] .
The diabetic subjects with no or minimal retinopathy had similar EDs0 values to those of the matched diabetic subjects with proliferative retinopathy. The plasma glucose concentrations of the subjects in these two subgroups were also similar. Poor diabetic control is associated with the development of microvascular disease [12] , and the glycosylated haemoglobin levels of the diabetic patients with no or minimal retinopathy tended to be lower than those with proliferative retinopathy. A prospective study might allow better assessment of the relationship between diabetic control, platelet sensitivity to pro-aggregating agents and the progression of diabetic microvascular disease.
The collision theory model allowed a formal comparison of the platelet prostacyclin sensitivity of nondiabetic and diabetic subjects, even though the ADP sensitivity of platelets from the diabetic patients was increased in the absence of this antagonist. The platelet prostacyclin sensitivity of the diabetic subjects in both retinopathy subgroups was similar to that of the nondiabetic subjects. This finding does not support reports of decreased prostacyclin sensitivity in diabetes [6] , which has been found to be most marked in the present of vascular complications [7] . These studies were concemed with platelet prostacyclin sensitivity at a single ADP dose, without regard for differences in ADP sensitivity between diabetic and non-diabetic subjects.
The results of the present study support the suggestion that platelets from diabetic patients are hypersensitive to ADP, a situation which might contribute to the development of diabetic angiopathy. However, there seems insufficient evidence to implicate reduced prostacyclin production or anti-aggregatory effect in this process.
